西藏药业(600211) - 2018 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders was CNY 68,663,314.76, an increase of 26.84% year-on-year[6]. - Operating revenue for the period was CNY 212,739,071.59, down 13.40% from the previous year[6]. - Net profit for Q1 2018 was CNY 69,072,604.83, representing an increase of 25.6% from CNY 54,992,094.63 in the previous year[26]. - The company's operating revenue for Q1 2018 was ¥53,530,589.13, a significant increase of 180.0% compared to ¥19,118,150.24 in the same period last year[28]. - The net profit for Q1 2018 reached ¥60,508,074.56, compared to ¥4,299,114.30 in Q1 2017, representing a year-over-year increase of 1,308.5%[28]. - The total comprehensive income for the period was ¥60,710,977.27, compared to ¥4,664,474.33 in the same quarter last year, reflecting a growth of 1,200.0%[28]. Cash Flow - Net cash flow from operating activities was CNY 57,631,036.26, a significant increase of 811.90% compared to the same period last year[6]. - Net cash flow from operating activities increased by 65.73 million yuan, a growth of 811.90%, mainly due to increased sales receipts and government subsidies received[14]. - Cash flow from operating activities generated a net amount of ¥57,631,036.26, a turnaround from a negative cash flow of ¥8,095,430.44 in the same quarter last year[31]. - Net cash flow from investment activities was -$9,637,833.96, a decline from $10,388,534.14 in the previous year[35]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,315,615,529.15, a decrease of 0.62% compared to the end of the previous year[6]. - Total assets as of March 31, 2018, amounted to CNY 2,140,488,033.51, up from CNY 2,088,641,173.24 at the beginning of the year[23]. - Total liabilities decreased to CNY 68,117,091.32 from CNY 76,981,208.32, reflecting a reduction of 11.5%[24]. - The company's total equity increased to CNY 2,072,370,942.19, up from CNY 2,011,659,964.92, marking a growth of 3.0%[24]. Shareholder Information - The number of shareholders at the end of the reporting period was 13,557[9]. - The top shareholder, Tibet Kangzhe Enterprise Management Co., Ltd., held 31.83% of the shares[9]. Expenses and Income - Management expenses rose by 55.68% to CNY 15,169,872.55 compared to the previous period[11]. - Income tax expenses increased by 4.55 million yuan, a growth of 106.46%, primarily due to an increase in total profit compared to the previous period[13]. - Financial expenses decreased by 4.21 million yuan, a decline of 276.18%, primarily due to the absence of interest expenses from the subsidiary TopRidge Pharma Limited in the current period[13]. - Investment income decreased by 1.32 million yuan, a decline of 727.72%, mainly due to increased losses from associated companies compared to the previous period[13]. Other Comprehensive Income - Other comprehensive income decreased by CNY 50,590,132.54, reflecting significant foreign exchange fluctuations[11]. - Other comprehensive income after tax was CNY -50,590,132.54, a significant decrease from CNY 840,197.08 in the previous year[26]. Government Support - The company received government support funds of 28.77 million yuan during the reporting period[16].